JP2006508970A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508970A5 JP2006508970A5 JP2004552632A JP2004552632A JP2006508970A5 JP 2006508970 A5 JP2006508970 A5 JP 2006508970A5 JP 2004552632 A JP2004552632 A JP 2004552632A JP 2004552632 A JP2004552632 A JP 2004552632A JP 2006508970 A5 JP2006508970 A5 JP 2006508970A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- optionally substituted
- trifluoromethyl
- alkoxy
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 19
- 206010020772 Hypertension Diseases 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 claims description 7
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 claims description 7
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 201000006370 kidney failure Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 5
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 5
- 206010016654 Fibrosis Diseases 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 208000019025 Hypokalemia Diseases 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 208000029078 coronary artery disease Diseases 0.000 claims description 5
- 230000008694 endothelial dysfunction Effects 0.000 claims description 5
- 230000004761 fibrosis Effects 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 208000024896 potassium deficiency disease Diseases 0.000 claims description 5
- 238000007634 remodeling Methods 0.000 claims description 5
- 208000037803 restenosis Diseases 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 239000000883 anti-obesity agent Substances 0.000 claims description 4
- 239000002220 antihypertensive agent Substances 0.000 claims description 4
- 229940030600 antihypertensive agent Drugs 0.000 claims description 4
- 239000003524 antilipemic agent Substances 0.000 claims description 4
- 229940125710 antiobesity agent Drugs 0.000 claims description 4
- 239000000496 cardiotonic agent Substances 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- HMNQDXFMYVAXKB-UHFFFAOYSA-N 5-naphthalen-1-ylimidazo[1,5-a]pyridine Chemical compound C1=CC=C2C(C=3N4C=NC=C4C=CC=3)=CC=CC2=C1 HMNQDXFMYVAXKB-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 13
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000004432 carbon atom Chemical group C* 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- -1 Benzylfuran-3-yl-imidazo [1,5-a] pyridine Chemical compound 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- PLSQRYHAFQEEBB-UHFFFAOYSA-N 5-(2-phenylphenyl)imidazo[1,5-a]pyridine Chemical compound C=1C=CC2=CN=CN2C=1C1=CC=CC=C1C1=CC=CC=C1 PLSQRYHAFQEEBB-UHFFFAOYSA-N 0.000 claims 1
- NWFCFXALXRKBCD-UHFFFAOYSA-N 5-(4-phenylphenyl)imidazo[1,5-a]pyridine Chemical compound C=1C=CC2=CN=CN2C=1C(C=C1)=CC=C1C1=CC=CC=C1 NWFCFXALXRKBCD-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000000243 solution Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- OVBYYFFTIMPHGS-UHFFFAOYSA-N 5-naphthalen-1-ylimidazo[1,5-a]pyridine;hydrochloride Chemical compound Cl.C1=CC=C2C(C=3N4C=NC=C4C=CC=3)=CC=CC2=C1 OVBYYFFTIMPHGS-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
- IPOYUTJDAMAUNH-UHFFFAOYSA-N 2h-imidazo[1,5-a]pyridine-3-thione Chemical compound C1=CC=CN2C(=S)NC=C21 IPOYUTJDAMAUNH-UHFFFAOYSA-N 0.000 description 1
- MWLUCKLACUXRMF-UHFFFAOYSA-N C1(=CC=CC=C1)N=C=S.C=1N=C(N2C1C=CC=C2)S Chemical compound C1(=CC=CC=C1)N=C=S.C=1N=C(N2C1C=CC=C2)S MWLUCKLACUXRMF-UHFFFAOYSA-N 0.000 description 1
- LXZWMWPSQUAIMT-UHFFFAOYSA-N C1=CC=C2C(=C1)C=CC=C2C3=CC=CC4=C(N=CN43)S Chemical compound C1=CC=C2C(=C1)C=CC=C2C3=CC=CC4=C(N=CN43)S LXZWMWPSQUAIMT-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42732502P | 2002-11-18 | 2002-11-18 | |
| PCT/EP2003/012851 WO2004046145A1 (en) | 2002-11-18 | 2003-11-17 | Imidazo[1, 5a]pyridine derivatives and methods for treating aldosterone mediated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508970A JP2006508970A (ja) | 2006-03-16 |
| JP2006508970A5 true JP2006508970A5 (enExample) | 2006-12-28 |
Family
ID=32326521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004552632A Pending JP2006508970A (ja) | 2002-11-18 | 2003-11-17 | イミダゾ［１，５ａ］ピリジン誘導体およびアルデステロンにより仲介される疾患の処置方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7223866B2 (enExample) |
| EP (1) | EP1565463B1 (enExample) |
| JP (1) | JP2006508970A (enExample) |
| CN (1) | CN100447142C (enExample) |
| AT (1) | ATE398124T1 (enExample) |
| AU (1) | AU2003292039A1 (enExample) |
| BR (1) | BR0316306A (enExample) |
| CA (1) | CA2505752A1 (enExample) |
| DE (1) | DE60321593D1 (enExample) |
| ES (1) | ES2305520T3 (enExample) |
| PT (1) | PT1565463E (enExample) |
| WO (1) | WO2004046145A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004052846A1 (en) * | 2002-12-06 | 2004-06-24 | Bayer Healthcare Ag | Tetrahydro-naphthalene derivatives |
| DK1572632T3 (da) | 2002-12-09 | 2008-10-27 | Xention Ltd | Tetrahydro-naphthalenderivater som vanilloidreceptorantagonister |
| WO2006092430A1 (de) * | 2005-03-03 | 2006-09-08 | Universität des Saarlandes | Selektive hemmstoffe humaner corticoidsynthasen |
| TW200716634A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| TW200716105A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
| TW200716636A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| GT200600381A (es) * | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| EP1842543A1 (en) | 2006-04-05 | 2007-10-10 | Speedel Pharma AG | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist |
| US7803810B2 (en) * | 2007-03-09 | 2010-09-28 | Probiodrug Ag | Inhibitors |
| CN101910171A (zh) | 2007-11-01 | 2010-12-08 | 百时美施贵宝公司 | 可用作糖皮质激素受体AP-1和/或者NF-κB活性调节剂的非甾类化合物及其用途 |
| EP2095819A1 (en) | 2008-02-28 | 2009-09-02 | Maastricht University | N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors |
| SG176010A1 (en) | 2009-05-28 | 2011-12-29 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
| JP5420761B2 (ja) | 2009-05-28 | 2014-02-19 | ノバルティス アーゲー | ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体 |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| US8575160B2 (en) | 2009-11-30 | 2013-11-05 | Novartis Ag | Imidazole derivatives as aldosterone synthase inhibitors |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| PL2729142T3 (pl) | 2011-07-08 | 2018-10-31 | Novartis Ag | Sposób leczenia miażdżycy tętnic u osobników z wysokim poziomem triglicerydów |
| US9193724B2 (en) | 2011-09-22 | 2015-11-24 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
| WO2013043521A1 (en) | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Pyrazolopyridyl compounds as aldosterone synthase inhibitors |
| US20140235667A1 (en) | 2011-09-22 | 2014-08-21 | Merck Sharp & Dohme Corp. | Imidazopyridyl compounds as aldosterone synthase inhibitors |
| IN2014DN06781A (enExample) | 2012-01-17 | 2015-05-22 | Novartis Ag | |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| NZ710574A (en) | 2013-02-14 | 2017-11-24 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors |
| BR112016001376A2 (pt) | 2013-07-25 | 2017-10-24 | Novartis Ag | bioconjugados de polipeptídeos de apelin sintéticos |
| US9266925B2 (en) | 2013-07-25 | 2016-02-23 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
| CA2972871A1 (en) | 2015-01-23 | 2016-07-28 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
| GB201511790D0 (en) * | 2015-07-06 | 2015-08-19 | Iomet Pharma Ltd | Pharmaceutical compound |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| CN113166101A (zh) | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状五聚体化合物 |
| JP7657151B2 (ja) | 2018-11-27 | 2025-04-04 | ノバルティス アーゲー | 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| TW202333563A (zh) | 2021-11-12 | 2023-09-01 | 瑞士商諾華公司 | 用於治療疾病或障礙之二胺基環戊基吡啶衍生物 |
| AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
| US20240391941A1 (en) | 2023-05-24 | 2024-11-28 | Novartis Ag | Naphthyridinone derivatives for the treatment of a disease or disorder |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1250844A (en) * | 1981-06-22 | 1989-03-07 | Neville Ford | Substituted imidazo¬1,5-a|pyridines, process for their manufacture, pharmaceutical preparations containing these compounds and their therapeutic application |
| US5428160A (en) * | 1982-12-21 | 1995-06-27 | Ciba-Geigy Corporation | Substituted imidazo[5-a]pyridine derviatives and other substituted bicyclic derivatives |
| US4617307A (en) * | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
| US4470986A (en) * | 1982-12-21 | 1984-09-11 | Ciba-Geigy Corporation | Certain imidazo (1,5-A) pyridine aliphatic carboxylic acid derivatives and their use as selective thromboxane inhibitors |
| US4588732A (en) * | 1982-12-21 | 1986-05-13 | Ciba-Geigy Corporation | Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors |
| US4889861A (en) * | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
| JPS615076A (ja) * | 1984-06-19 | 1986-01-10 | Toyama Chem Co Ltd | 新規な１，４−ジヒドロピリジン誘導体およびその塩 |
| GB8510541D0 (en) * | 1985-04-25 | 1985-05-30 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| US5798364A (en) * | 1992-03-26 | 1998-08-25 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Imidazopyridines |
| US5529992A (en) * | 1992-04-21 | 1996-06-25 | Curators Of The University Of Missouri | Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors |
| US6150347A (en) * | 1992-04-21 | 2000-11-21 | The Curators Of The University Of Missouri | Use of aldosterone antagonists to inhibit myocardial fibrosis |
| JPH0971586A (ja) | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | 新規な二環性縮合イミダゾール誘導体 |
| DE19701257A1 (de) * | 1997-01-17 | 1998-07-23 | Hannecke Wolf D Kunststoff | Säulenpräsentationssystem in Modulbauweise zur Schaustellung von Waren oder Prospektmaterial und insbesondere von dünnen Gegenständen |
| US6887870B1 (en) | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
-
2003
- 2003-11-17 CA CA002505752A patent/CA2505752A1/en not_active Abandoned
- 2003-11-17 CN CNB2003801035050A patent/CN100447142C/zh not_active Expired - Fee Related
- 2003-11-17 ES ES03767563T patent/ES2305520T3/es not_active Expired - Lifetime
- 2003-11-17 US US10/534,631 patent/US7223866B2/en not_active Expired - Fee Related
- 2003-11-17 JP JP2004552632A patent/JP2006508970A/ja active Pending
- 2003-11-17 BR BR0316306-7A patent/BR0316306A/pt not_active IP Right Cessation
- 2003-11-17 EP EP03767563A patent/EP1565463B1/en not_active Expired - Lifetime
- 2003-11-17 AT AT03767563T patent/ATE398124T1/de not_active IP Right Cessation
- 2003-11-17 PT PT03767563T patent/PT1565463E/pt unknown
- 2003-11-17 WO PCT/EP2003/012851 patent/WO2004046145A1/en not_active Ceased
- 2003-11-17 AU AU2003292039A patent/AU2003292039A1/en not_active Abandoned
- 2003-11-17 DE DE60321593T patent/DE60321593D1/de not_active Expired - Lifetime
-
2007
- 2007-04-24 US US11/739,290 patent/US7713991B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5135235B2 (ja) | Ｖａｌ−４によって媒介される白血球の接着を阻害するピリミジニルスルホンアミド化合物 | |
| JP6409004B2 (ja) | ソルチリン阻害剤としてのｎ置換された５置換フタルアミド酸 | |
| KR101739361B1 (ko) | 1,2 나프토퀴논 유도체 및 이의 제조방법 | |
| EP2919779B1 (en) | Cannabinoid receptor mediating compounds | |
| CZ294648B6 (cs) | Pyridin-substituované deriváty pyrazolpyridinu, způsob jejich výroby, léčiva tyto látky obsahující a jejich použití | |
| JP2015164925A (ja) | キナーゼ活性の阻害剤 | |
| JPH04235149A (ja) | アシル化合物 | |
| KR20120028869A (ko) | β-세크레타제 억제제로서 치환된 이미다조［1,2-Ａ］피리딘 유도체, 약제학적 조성물, 및 사용 방법 | |
| JP2008534479A (ja) | Ｈｃｖの複素二環式阻害剤 | |
| WO2023061415A1 (en) | Thiadiazolyl derivatives, compositions and uses thereof | |
| JP2006508970A (ja) | イミダゾ［１，５ａ］ピリジン誘導体およびアルデステロンにより仲介される疾患の処置方法 | |
| JP2012530765A (ja) | 結核を処置するための組成物 | |
| JPH06293741A (ja) | 複素環置換フエニルシクロヘキサンカルボン酸誘導体 | |
| EP2158194B1 (fr) | Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique | |
| US6362195B1 (en) | Branched alkoxy-substituted 2-aminopyridines as NOS inhibitors | |
| TW201902885A (zh) | 肝ｘ受體（ｌｘｒ）調節劑 | |
| KR20070045272A (ko) | 2-페닐피리딘 유도체 | |
| JP2022542144A (ja) | アセチル補酵素ａシンテターゼ短鎖２（ａｃｓｓ２）の小分子阻害剤 | |
| WO2004000813A1 (ja) | フェノキシピリジン誘導体又はその塩 | |
| JP5149794B2 (ja) | 飽和リンカー基を含有するヘテロアリール置換アミドおよび医薬としてのその使用 | |
| WO2018126072A1 (en) | Heterocyclic integrin agonists | |
| FR2985185A1 (fr) | Utilisation en therapeutique de derives d'imidazopyridine | |
| KR20230038193A (ko) | 치료용 단백질 키나아제 억제제 용도의 2-옥소-n-(4-(피리미딘-4-일옥시/티오)페닐)-1,2-디하이드로피리딘-3-카복사아마이드 유도체 | |
| TW201031659A (en) | Novel compound having 3-(5-alkoxypyrimidin-2-yl) pyrimidin-4(3H)-on structure and medicine containg same | |
| TWI918959B (zh) | 化合物、內皮素a受體拮抗劑及醫藥組合物 |